{"id":450657,"date":"2021-03-04T08:11:02","date_gmt":"2021-03-04T13:11:02","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450657"},"modified":"2021-03-04T08:11:02","modified_gmt":"2021-03-04T13:11:02","slug":"psybio-therapeutics-announces-retention-of-market-maker","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/","title":{"rendered":"PsyBio Therapeutics Announces Retention of Market Maker"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO, March  04, 2021  (GLOBE NEWSWIRE) &#8212; PsyBio Therapeutics Corp.\u00a0(TSXV:PSYB)\u00a0(\u201c<strong>PsyBio<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a leader in the field\u00a0of psychedelic research\u00a0and drug development, announces\u00a0that, subject to the\u00a0receipt of approval by the TSX Venture Exchange (\u201c<strong>TSXV<\/strong>\u201d),\u00a0it has\u00a0retained\u00a0Generation IACP Inc. (\u201c<strong>Generation<\/strong>\u201d) to provide\u00a0market making services with\u00a0the objective of\u00a0maintaining a reasonable market and improving the\u00a0liquidity of PsyBio\u00a0shares traded on the TSXV.\u00a0PsyBio and Generation are unrelated and\u00a0unaffiliated\u00a0entities. Generation is a member of the\u00a0Investment Industry Regulation Organization of\u00a0Canada (IIROC) and a member firm of the TSXV.<\/p>\n<p align=\"justify\">Under the agreement between Generation and the Company (the \u201c<strong>Generation\u00a0Agreement<\/strong>\u201d), the Company has agreed to initially pay Generation a fee of\u00a0CAD$7,500\u00a0plus applicable taxes per month for a six-month term, subject to termination in accordance with the notice provisions provded for in the Generation Agreement. Generation will not receive any securities as compensation. Generation does not currently own any securities of PsyBio; however, Generation and its clients may acquire a direct interest in the securities of the Company.<\/p>\n<p align=\"justify\">\n        <strong>About PsyBio Therapeutics Corp. <\/strong>\n      <\/p>\n<p align=\"justify\">PsyBio is a biotechnology company developing novel formulations of psychoactive medications using genetically modified bacteria for the treatment of mental health and other disorders. The team has experience in drug discovery based on synthetic biology and clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development are currently ongoing for natural occurring tryptamines in different varieties of magic mushrooms, dimethyltryptamine and its derivatives, and mescaline and combinations thereof. The Company is also researching and developing new molecular structures that do not occur in nature which may have unique therapeutics properties.<\/p>\n<p>\n        <strong>Cautionary Note Regarding\u00a0Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains statements that constitute \u201cforward-looking information\u201d (\u201c<strong>forward-looking information<\/strong>\u201d) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as \u201cexpects\u201d, or \u201cdoes not expect\u201d, \u201cis expected\u201d, \u201canticipates\u201d or \u201cdoes not anticipate\u201d, \u201cplans\u201d, \u201cbudget\u201d, \u201cscheduled\u201d, \u201cforecasts\u201d, \u201cestimates\u201d, \u201cbelieves\u201d or \u201cintends\u201d or variations of such words and phrases or stating that certain actions, events or results \u201cmay\u201d or \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill\u201d be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: the retention of Generation will help maintain a reasonable market and improve the liquidity of PsyBio Shares traded on the TSXV; PsyBio will be successful in protecting its intellectual property within the next year and filing new patent applications within that timeframe; the Company\u2019s success in discovering new valuable target molecules; and the safety and efficacy of PsyBio\u2019s technology and that such technology will be cheaper, faster and greener than other published methods. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio\u2019s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.<\/p>\n<p align=\"justify\">PsyBio makes no medical, treatment or health benefit claims about PsyBio\u2019s proposed products. The U.S. Food and Drug Administration (the \u201c<strong>FDA<\/strong>\u201d) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products have not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio\u2019s performance and operations.<\/p>\n<p align=\"justify\">\n        <em>The\u00a0TSX Venture Exchange (the \u201cTSXV\u201d) has neither approved nor disapproved the contents of this news release. Neither the\u00a0TSXV\u00a0nor its Regulation Services Provider (as\u00a0that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>For further information contact:\u00a0<\/strong>\n      <\/p>\n<p>Evan Levine\u00a0<br \/>CEO, PsyBio Therapeutics Corp.\u00a0<br \/>t: 226.286.0348<br \/>e:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6Rb46ezHoqAM0uBSJYuA_6UDw8z-7xEsabs1_HFTH2r-mlXEg7muSyD6PNo3fgj7bVPFQEFUK3tsjH0m-8uy1xJOMwJzFNLmQrpxmrmlep-DJ2RIXcVogrQeqEL7FUIB1Vtm5I3uo1Yy4NF7gE188F7Hlqf3H2yxEYtipXODzur4knLzIN_1BrA6FzVuZlX25aCRwtR6r54ISw8-Mo91XI3tWQwwL3LHoDZYYe-ofHs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@psybiolife.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Enquiries:<\/strong>\n      <\/p>\n<p align=\"justify\">Kirsten Frazer, PhD<br \/>LifeSci Communications<br \/>t: 646.863.0222<br \/>e: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LEbj5LVbGHFpded3V_1RkWjU0FcW7oh1WMByM5sZ7TXGbgabfoIdY_AEhejWncaz5abQhFFa8l9dZ3TnooGfSdDDRawq0f_AnygQshFeaks=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kfrazer@lifescicomms.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/56efa17e-75b9-4ff4-b840-b51469951db5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, March 04, 2021 (GLOBE NEWSWIRE) &#8212; PsyBio Therapeutics Corp.\u00a0(TSXV:PSYB)\u00a0(\u201cPsyBio\u201d or the \u201cCompany\u201d), a leader in the field\u00a0of psychedelic research\u00a0and drug development, announces\u00a0that, subject to the\u00a0receipt of approval by the TSX Venture Exchange (\u201cTSXV\u201d),\u00a0it has\u00a0retained\u00a0Generation IACP Inc. (\u201cGeneration\u201d) to provide\u00a0market making services with\u00a0the objective of\u00a0maintaining a reasonable market and improving the\u00a0liquidity of PsyBio\u00a0shares traded on the TSXV.\u00a0PsyBio and Generation are unrelated and\u00a0unaffiliated\u00a0entities. Generation is a member of the\u00a0Investment Industry Regulation Organization of\u00a0Canada (IIROC) and a member firm of the TSXV. Under the agreement between Generation and the Company (the \u201cGeneration\u00a0Agreement\u201d), the Company has agreed to initially pay Generation a fee of\u00a0CAD$7,500\u00a0plus applicable taxes per month for a six-month term, subject to termination in accordance with the notice provisions provded for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PsyBio Therapeutics Announces Retention of Market Maker&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450657","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PsyBio Therapeutics Announces Retention of Market Maker - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PsyBio Therapeutics Announces Retention of Market Maker - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, March 04, 2021 (GLOBE NEWSWIRE) &#8212; PsyBio Therapeutics Corp.\u00a0(TSXV:PSYB)\u00a0(\u201cPsyBio\u201d or the \u201cCompany\u201d), a leader in the field\u00a0of psychedelic research\u00a0and drug development, announces\u00a0that, subject to the\u00a0receipt of approval by the TSX Venture Exchange (\u201cTSXV\u201d),\u00a0it has\u00a0retained\u00a0Generation IACP Inc. (\u201cGeneration\u201d) to provide\u00a0market making services with\u00a0the objective of\u00a0maintaining a reasonable market and improving the\u00a0liquidity of PsyBio\u00a0shares traded on the TSXV.\u00a0PsyBio and Generation are unrelated and\u00a0unaffiliated\u00a0entities. Generation is a member of the\u00a0Investment Industry Regulation Organization of\u00a0Canada (IIROC) and a member firm of the TSXV. Under the agreement between Generation and the Company (the \u201cGeneration\u00a0Agreement\u201d), the Company has agreed to initially pay Generation a fee of\u00a0CAD$7,500\u00a0plus applicable taxes per month for a six-month term, subject to termination in accordance with the notice provisions provded for &hellip; Continue reading &quot;PsyBio Therapeutics Announces Retention of Market Maker&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T13:11:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PsyBio Therapeutics Announces Retention of Market Maker\",\"datePublished\":\"2021-03-04T13:11:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/\"},\"wordCount\":914,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/\",\"name\":\"PsyBio Therapeutics Announces Retention of Market Maker - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=\",\"datePublished\":\"2021-03-04T13:11:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psybio-therapeutics-announces-retention-of-market-maker\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PsyBio Therapeutics Announces Retention of Market Maker\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PsyBio Therapeutics Announces Retention of Market Maker - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/","og_locale":"en_US","og_type":"article","og_title":"PsyBio Therapeutics Announces Retention of Market Maker - Market Newsdesk","og_description":"TORONTO, March 04, 2021 (GLOBE NEWSWIRE) &#8212; PsyBio Therapeutics Corp.\u00a0(TSXV:PSYB)\u00a0(\u201cPsyBio\u201d or the \u201cCompany\u201d), a leader in the field\u00a0of psychedelic research\u00a0and drug development, announces\u00a0that, subject to the\u00a0receipt of approval by the TSX Venture Exchange (\u201cTSXV\u201d),\u00a0it has\u00a0retained\u00a0Generation IACP Inc. (\u201cGeneration\u201d) to provide\u00a0market making services with\u00a0the objective of\u00a0maintaining a reasonable market and improving the\u00a0liquidity of PsyBio\u00a0shares traded on the TSXV.\u00a0PsyBio and Generation are unrelated and\u00a0unaffiliated\u00a0entities. Generation is a member of the\u00a0Investment Industry Regulation Organization of\u00a0Canada (IIROC) and a member firm of the TSXV. Under the agreement between Generation and the Company (the \u201cGeneration\u00a0Agreement\u201d), the Company has agreed to initially pay Generation a fee of\u00a0CAD$7,500\u00a0plus applicable taxes per month for a six-month term, subject to termination in accordance with the notice provisions provded for &hellip; Continue reading \"PsyBio Therapeutics Announces Retention of Market Maker\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T13:11:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PsyBio Therapeutics Announces Retention of Market Maker","datePublished":"2021-03-04T13:11:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/"},"wordCount":914,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/","name":"PsyBio Therapeutics Announces Retention of Market Maker - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=","datePublished":"2021-03-04T13:11:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ5NiM0MDQ3Nzc0IzIyMDc2ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psybio-therapeutics-announces-retention-of-market-maker\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PsyBio Therapeutics Announces Retention of Market Maker"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450657"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}